PALO
ALTO, Calif., Oct. 14,
2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq:
KOD), a biopharmaceutical company committed to researching,
developing and commercializing transformative therapeutics to treat
a broad spectrum of retinal diseases, announced today its
participation in a presentation and panel at Innovate Retina 2024
on October 17, 2024, in Chicago, Illinois.
Presentation and Panel details are below:
- Presentation Title: Update on Antibody Biopolymer Conjugates:
Optimizing Immediacy and Durability
Time: 3:30 PM CT
Presenter: Mark Barakat, M.D.,
FASRS, Clinical Assistant Professor of Ophthalmology, University of Arizona College of Medicine –
Phoenix; Founder and Director of
Research, Retina Macula Institute of Arizona; Medical Director, Spectra Eye
Institute
- Panel Title: The Future of Retinal Therapeutics
Time: 6:30 PM CT
Kodiak Panelist: Victor Perlroth,
M.D., Chairman and Chief Executive Officer
Slides of the presentation will be made available on the "Events
and Presentations" section of Kodiak's website at
http://ir.kodiak.com/ at the beginning of the
presentation.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical company
committed to researching, developing, and commercializing
transformative therapeutics to treat a broad spectrum of retinal
diseases. We are focused on bringing new science to the design and
manufacture of next generation retinal medicines to prevent and
treat the leading causes of blindness globally. Our ABCD Platform™
uses molecular engineering to merge the fields of protein-based and
chemistry-based therapies and has been at the core of Kodiak's
discovery engine. We are developing a portfolio of three clinical
programs, two of which are late-stage today and derived from our
ABCD Platform and one which is platform-independent and which we
believe can progress rapidly into pivotal studies.
Kodiak's lead investigational medicine, tarcocimab, is a novel
anti-VEGF antibody biopolymer conjugate under development for the
treatment of high prevalence retinal vascular diseases. Tarcocimab
is currently being studied in two Phase 3 clinical trials, GLOW2 in
patients with diabetic retinopathy and DAYBREAK in patients with
wet AMD. Both studies are actively enrolling patients.
KSI-501 is our second investigational medicine, a first-in-class
anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate
designed to inhibit both IL-6 mediated inflammation and
VEGF-mediated angiogenesis and vascular permeability. KSI-501 is
being developed for the treatment of high prevalence retinal
vascular diseases to address the unmet needs of extended durability
and targeting multiple disease biologies for differentiated
efficacy. The Phase 3 DAYBREAK study of KSI-501 in wet AMD is
actively enrolling patients.
KSI-101, our third product candidate, is a novel anti-IL-6,
VEGF-trap bispecific protein. Kodiak is developing KSI-101 for the
treatment of retinal inflammatory diseases, as currently there are
no available intravitreal biologic therapies addressing the
spectrum of inflammatory conditions of the retina. The Phase
1b APEX study of KSI-101 is actively
enrolling patients, as a precursor to activating the Phase
2b/3 PEAK and PINNACLE studies in
patients with macular edema secondary to inflammation (MESI).
For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak
logo are registered trademarks or trademarks of Kodiak Sciences
Inc. in various global jurisdictions.
View original
content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-innovate-retina-2024-302275636.html
SOURCE Kodiak Sciences Inc.
